« Back

Mavenclad (Cladribine Tablets)

Fitted

Monday July 23 2018 05:25 PM

New treatment option for relapsing remitting MS

The National Centre for Pharmacoeconomics in Ireland (NCPE) announces positive recommendation for reimbursement for MAVENCLAD (Cladribine tablets). 

MS Ireland believes people with MS should have access to all and any appropriate and licensed treatments that would improve or assist in the management of their condition. The MS community is very much looking forward to having access to this treatment option.

Read MS Ireland’s briefing document on the process of licensing and reimbursement of new medications.

Author: MS Ireland

Tags: mavenclad, cladribinetablets

Comments

Add a comment

Your email address will not be published and will only be used by MS Ireland to contact you should there be an issue with your comment.

Please read our policy on making comments. Basically, respect other people’s view, use appropriate language and be nice! Comments are published between 9am and 5pm, Monday to Friday.

We ask this question to ensure that you are a real person, and not a computer adding information automatically.

By commenting, you are adhering to our Terms of use / Privacy

Latest News

More news

What's hot

Job_opps

We're Hiring

If you would like to be part of our team, take a look at our current job opportunities.

Find out more

Events Calendar

» Our next Event

20 October 2018: Physiotherapist led Exercise programme for people with MS.

View all events

eNEWS SIGNUP

If you'd like to receive e-news updates from The Society please enter your email address below. If you want to know more about how we manage personal data then please see our privacy policy.

My local MSI

Map of MS Ireland's service areas South Mid West West Midlands South East North East North West North Dublin City and Fingal South West Dublin and Kildare South East Dublin and Wicklow